Cooper Companies (NYSE:COO) had its target price increased by equities researchers at Piper Jaffray Companies from $330.00 to $360.00 in a research note issued on Tuesday, The Fly reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 8.19% from the company’s current price.

Other analysts also recently issued reports about the stock. Raymond James raised their price objective on shares of Cooper Companies from $325.00 to $364.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Wells Fargo & Co raised their price objective on shares of Cooper Companies from $356.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Northcoast Research restated a “buy” rating and set a $340.00 price objective (up from $331.00) on shares of Cooper Companies in a research report on Monday, June 3rd. Finally, Zacks Investment Research upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $336.00 price objective on the stock in a research report on Friday, June 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $322.91.

Shares of COO stock opened at $332.74 on Tuesday. The company has a market cap of $16.48 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.52 and a beta of 0.90. Cooper Companies has a one year low of $228.65 and a one year high of $344.32. The company’s fifty day moving average price is $334.02. The company has a quick ratio of 0.68, a current ratio of 1.21 and a debt-to-equity ratio of 0.42.

Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Thursday, May 30th. The medical device company reported $2.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.76 by $0.18. The firm had revenue of $654.30 million for the quarter, compared to the consensus estimate of $655.00 million. Cooper Companies had a net margin of 16.46% and a return on equity of 17.25%. The company’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm earned $2.86 EPS. As a group, equities analysts expect that Cooper Companies will post 12.28 earnings per share for the current year.

In related news, Director Jody S. Lindell sold 3,000 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $328.29, for a total transaction of $984,870.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride sold 11,981 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $315.99, for a total transaction of $3,785,876.19. Following the transaction, the chief operating officer now directly owns 42,668 shares of the company’s stock, valued at $13,482,661.32. The disclosure for this sale can be found here. Insiders have sold 77,678 shares of company stock valued at $25,063,536 over the last ninety days. 1.70% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of COO. Veritas Asset Management LLP grew its stake in Cooper Companies by 77.8% during the first quarter. Veritas Asset Management LLP now owns 981,302 shares of the medical device company’s stock valued at $290,632,000 after acquiring an additional 429,340 shares in the last quarter. Swedbank purchased a new position in shares of Cooper Companies in the 2nd quarter worth $100,362,000. Prudential Financial Inc. grew its stake in shares of Cooper Companies by 330.9% in the 2nd quarter. Prudential Financial Inc. now owns 297,402 shares of the medical device company’s stock worth $100,192,000 after buying an additional 228,380 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Cooper Companies by 4.3% in the 2nd quarter. Vanguard Group Inc. now owns 5,566,546 shares of the medical device company’s stock worth $1,875,314,000 after buying an additional 227,435 shares in the last quarter. Finally, Marshall Wace North America L.P. grew its stake in shares of Cooper Companies by 115.1% in the 2nd quarter. Marshall Wace North America L.P. now owns 420,179 shares of the medical device company’s stock worth $141,554,000 after buying an additional 224,844 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: What is a Special Dividend?

The Fly

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.